Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03933163
Other study ID # 36007
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 23, 2019
Est. completion date March 28, 2024

Study information

Verified date May 2024
Source Murdoch Childrens Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to assess the efficacy of micronised resveratrol as a treatment for FRDA, in terms of reducing the severity of ataxia symptoms at 24 weeks, through a randomised blinded, placebo controlled crossover trial.


Description:

Friedreich ataxia (FRDA) is the most common hereditary ataxia, with an estimated prevalence in Caucasians of 1 in 30,000. Neurological features of FRDA are progressive gait and limb ataxia, absent lower limb reflexes, and loss of position and vibration sense. There are currently no treatments proven to alter the natural history of FRDA. Resveratrol is a naturally occurring compound found in red wine, berries, and nuts. It is postulated to have wide-ranging health benefits, including antioxidant, anticarcinogenic, antidiabetic and neuroprotective properties. The study will be a double-blinded, placebo-controlled randomised 2-period crossover trial of 2g/day of micronised resveratrol in FRDA over 24 weeks. The study will enrol 40 patients with FRDA from 3 sites. The primary outcome measure is the change in modified Friedreich Ataxia Rating Scale (mFARS) score from baseline to 24 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date March 28, 2024
Est. primary completion date March 28, 2024
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: 1. Age =16 years. 2. Diagnosis of FRDA, genetically documented to be due to homozygosity for a GAA repeat expansion in intron 1 of FXN. 3. Functional stage on the Ataxia subscale of the full FARS of 1 or higher (a score of 1 is assigned if the subject has "Minimal signs detected by the physician during screening. Can run or jump without loss of balance. No disability."), and total mFARS score of = 65. 4. Adequate end organ function defined as follows: (i) total bilirubin <2x upper limit of normal unless attributable to Gilbert disease, (ii) ALT and AST <1.5x upper limit of normal, (iii) Creatinine <2x upper limit of normal, (iv) neutrophils >1.5x10^9/L, (v) platelets >10^6/µL. 5. Written informed consent provided. Exclusion Criteria: 1. Non-elective hospitalisation within the past 60 days that could be of concern in the investigator's judgment. Any hospitalisation in the previous 60 days will be assessed and if in the investigator's judgement it could compromise the individual or the study, that person will not be recruited. Examples include if the individual is hospitalised for management of cardiac morbidity such as uncontrolled arrhythmia or angina or for orthopaedic surgery for a lower limb fracture. 2. Women who are pregnant or lactating or men and women of childbearing potential who are unwilling to use contraception for the duration of the study. 3. FRDA due to compound heterozygosity for an expanded GAA repeat and a point mutation/ deletion in the FXN gene. 4. Current or recent (in last 12 months) arrhythmias including: atrial fibrillation, atrial flutter, sinus tachycardia >120/min, sinus bradycardia <50/min. Symptomatic paroxysmal arrhythmia which is recurring frequently. Cardiac insufficiency (by New York Heart Association >2). Reduced LV ejection fraction (<50%) in the last six months. 5. Medical illness that in the judgment of the investigator would jeopardise the safe completion of the study. Examples include cancer, chronic inflammatory disease, severe diabetes (type I or II, HbA1c >8%), chronic liver insufficiency, epilepsy, thrombocytosis. 6. Evidence of end organ dysfunction through failure to meet one or more parameters in inclusion criterion number 4. 7. Prior invasive cancer (excluding localised basal cell or squamous cell skin cancer). 8. Known hypersensitivity to resveratrol. 9. Use of any investigational agent within 30 days of enrolment. 10. Use of antioxidants such as vitamin E, coenzyme Q10 or idebenone within 30 days prior to enrolment. 11. Concomitant use of medications with potential for clinically relevant drug interactions. This includes medications with a narrow therapeutic range that are metabolised by the cytochrome P450 3A4, 2D6 or 2C9 systems e.g. warfarin, amiodarone.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Resveratrol
Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-[2-(4-hydroxyphenyl)ethenyl]-, (E). Ingredients: 99.50% pure trans-resveratrol. Placebo capsules will be identical in terms of taste, smell, and appearance.

Locations

Country Name City State
Australia University of Queensland Centre for Clinical Research Herston Queensland
Australia Murdoch Children's Research Institute Parkville Victoria
Australia Royal Perth Hospital Perth Western Australia
Australia Royal North Shore Hospital St Leonards New South Wales

Sponsors (1)

Lead Sponsor Collaborator
Murdoch Childrens Research Institute

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Modified Friedreich Ataxia Rating Scale Change in the Modified Friedreich Ataxia Rating Scale score (score range 0-99) at 24 weeks compared with baseline. Higher scores are indicative of more severe disease. 24 weeks
Secondary Nine-Hole Peg Test Change in the Nine-Hole Peg Test at 24 weeks compared with baseline. 24 weeks
Secondary Berg Balance Scale Change in the Berg Balance Scale (score range 0-56) at 24 weeks compared with baseline. A higher score indicates lower fall risk. 24 weeks
Secondary Ataxia Instrumented Measure-Spoon Change in the Ataxia Instrumented Measure-Spoon at 24 weeks compared with baseline. 24 weeks
Secondary Friedreich Ataxia Impact Scale Change in the Friedreich Ataxia Impact Scale at 24 weeks compared with baseline. The Friedreich Ataxia Impact Scale comprises 8 subscales (score range 0-100) that are scored independently. A higher score indicates greater impact of Friedreich ataxia on health and well-being. 24 weeks
Secondary Modified Fatigue Impact Scale Change in the Modified Fatigue Impact Scale (score range 0-24) at 24 weeks compared with baseline. Higher scores indicate a greater impact of fatigue on an individual's activities. 24 weeks
Secondary Measures of speech Change in measures of speech (reading a paragraph, produce a prolonged vowel sound for 5 seconds, count from one to 20, and produce a 1-minute monologue on a pre-specified topic) at 24 weeks compared with baseline. 24 weeks
Secondary Measures of hearing Change in measures of hearing using the Listening in Spatialized Noise Test (LiSN-S) at 24 weeks compared with baseline. 24 weeks
Secondary Cardiac parameters measured by echocardiography Change in left ventricular global longitudinal strain at 24 weeks compared to baseline. 24 weeks
Secondary Cardiac parameters measured by ECG Change in QRS duration at lead V5 at 24 weeks compared to baseline. 24 weeks
Secondary Frataxin levels Change in frataxin levels at 24 weeks compared to baseline. 24 weeks
Secondary mRNA levels Change in PGC-1a mRNA levels and Nrf2 mRNA levels at 24 weeks compared to baseline. 24 weeks
Secondary Plasma F2-isoprostane levels Change in plasma F2-isoprostane levels at 24 weeks compared to baseline. 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT05573698 - Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia Phase 1
Completed NCT00229632 - Idebenone to Treat Friedreich's Ataxia Phase 2
Completed NCT05579691 - A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia Phase 2
Completed NCT04273165 - Safety and Efficacy of Etravirine in Friedreich Ataxia Patients Phase 2
Not yet recruiting NCT05874388 - Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia N/A
Completed NCT02594917 - Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension
Completed NCT01716221 - An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia Phase 4
Active, not recruiting NCT05485987 - A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia Phase 2
Completed NCT03214588 - Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia Phase 2
Completed NCT03418740 - Neurology Measures in FA Children
Not yet recruiting NCT06054893 - A Study of Omaveloxolone in Children With Friedreich's Ataxia Phase 1
Recruiting NCT04921930 - Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) Phase 1/Phase 2
Completed NCT02705547 - Rosuvastatin (Crestor) in Friedreich Ataxia Early Phase 1
Completed NCT02035020 - A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients Phase 2
Completed NCT00015808 - Safety Study of Idebenone to Treat Friedreich's Ataxia Phase 1
Completed NCT04817111 - NAD+ Precursor Supplementation in Friedreich's Ataxia Phase 2
Active, not recruiting NCT05168774 - FRDA Investigator Initiated Study (IIS) With Elamipretide Phase 1/Phase 2
Completed NCT03917225 - A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients Phase 2
Completed NCT00224640 - Iron-Chelating Therapy and Friedreich Ataxia Phase 1/Phase 2
Completed NCT00056186 - Transitional Life Events in Patients With Friedreich's Ataxia: Implications for Genetic Counseling N/A